00000

( DrugBank: - / KEGG DRUG: - )

2 diseases

ID	Disease name (Link within this page)	Number of trials
6	Parkinson disease	2

ID	Disease name (Link within this page)	Number of trials
96	Crohn disease	2

6. Parkinson disease

Clinical trials : 2,307 / Drugs : 2,007 - (DrugBank : 349) / Drug target genes : 188 - Drug target pathways : 199

trials per page:

Showing 1 to 2 of 2 trials

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2016-000657-12-IT (EUCTR)	16/02/2017	08/02/2017	A Global Study to Assess the Drug Dynamics, Efficacy, and Safety of GZ/SAR402671 in Parkinson's Dise ...	Multicenter, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy, Safety, Phar ...	Parkinson's disease (PD) carrying a GBA mutation MedDRA version: 19.1;Level: PT;Classification code ...	Product Code: SAR402671, GZ402671 or GZ/SAR402671 INN or Proposed INN: 000000 Other descriptive name: ...	Genzyme Corporation	NULL	Not Recruiting			Female: yes Male: yes	276	Phase 2	United States;Portugal;Taiwan;Greece;Spain;Austria;Israel;United Kingdom;Italy;France;Canada;Singapo ...
2	NCT02838797 (ClinicalTrials.gov)	June 2016	16/6/2016	RQ-00000010 for Gastroparesis and Constipation in Parkinson's Disease	RQ-00000010 for Gastroparesis and Constipation in Parkinson's Disease	Parkinson's Disease;Gastroparesis;Constipation	Drug: RQ-00000010;Drug: Placebo	Virginia Commonwealth University	Michael J. Fox Foundation for Parkinson's Research;RaQualia Pharma Inc.	Completed	18 Years	N/A	All	51	Phase 1	United States

Clinical trials : 2,442 / Drugs : 1,278 - (DrugBank : 248) / Drug target genes : 142 - Drug target pathways : 209

trials per page:

Showing 1 to 2 of 2 trials

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2019-001087-30-IT (EUCTR)	10/09/2019	17/01/2022	Evaluating efficacy and safety of subcutaneous CT-P13 (CT-P13 SC) as maintenance therapy in patients ...	A Randomized, Placebo-Controlled, Double-Blind, Phase 3 Study to Evaluate the Efficacy and Safety of ...	Moderately to Severely Active Crohn's Disease MedDRA version: 20.0;Level: PT;Classification code 100 ...	Trade Name: Inflectra Product Name: / Product Code: [CT-P13] INN or Proposed INN: INFLIXIMAB Trade Name: ...	CELLTRION INC.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	600	Phase 3	United States;Belarus;Serbia;Slovakia;Greece;Spain;Ukraine;Israel;Chile;Russian Federation;Italy;Ind ...
2	EUCTR2014-004132-20-Outside-EU/EEA (EUCTR)		28/07/2016	Phase III study to assess efficacy and safety of D9421-C 9 mg with active Crohn’s Disease in Japan	A multicentre, double-blind, randomised, parallel-group, Phase III study to assess efficacy and safe ...	Active Crohn’s Disease MedDRA version: 19.0;Level: PT;Classification code 10011401;Term: Crohn's dis ...	Product Name: Entocort Product Code: D9421-C INN or Proposed INN: budesonide Trade Name: Pentasa INN or ...	AstraZeneca K.K.	NULL	NA			Female: yes Male: yes	112	Phase 3	Japan